Haloperidol Decanoate
A long-acting injectable formulation of haloperidol in which the drug is esterified with decanoic acid to create a depot preparation administered every two to four weeks for the maintenance treatment of schizophrenia and bipolar disorder. This formulation improves medication adherence by eliminating the need for daily dosing. It provides sustained antipsychotic coverage, making it particularly valuable for patients with a history of non-compliance.
Masse moléculaire
530,1000 g/mol
LogP
7,90
TPSA
46,60 Ų
Règle des 5 de Lipinski
Non conforme
Aires thérapeutiques
Mécanisme d'action
Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal side effects.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal …
Structure 2D
Cite this structure
Embed this structure
SMILES
CCCCCCCCCC(=O)OC1(c2ccc(Cl)cc2)CCN(CCCC(=O)c2ccc(F)cc2)CC1
InChI
InChI=1S/C31H41ClFNO3/c1-2-3-4-5-6-7-8-11-30(36)37-31(26-14-16-27(32)17-15-26)20-23-34(24-21-31)22-9-10-29(35)25-12-18-28(33)19-13-25/h12-19H,2-11,20-24H2,1H3
Molecular Formula
C31H41ClFNO3
HBD / HBA
- / 5
Liaisons Rotatives
16
Atomes Lourds
37
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Foire aux questions
A long-acting injectable formulation of haloperidol in which the drug is esterified with decanoic acid to create a depot preparation administered every two to four weeks for the maintenance treatment of schizophrenia and bipolar disorder. This formulation improves medication adherence by eliminating the need for daily dosing. It provides sustained antipsychotic coverage, making it particularly valuable for patients with a history of non-compliance.
Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal side effects.
Yes, Haloperidol Decanoate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1200986. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 52919. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="haloperidol-decanoate"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/haloperidol-decanoate/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/haloperidol-decanoate/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/haloperidol-decanoate/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="haloperidol-decanoate"></drugfyi-drug>